Johnson & Johnson's ($JNJ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are met--for a midstage blood-cancer treatment. Report
| Published: July 25, 2014 | Presented by: One 2 One
Cross-contamination among production lines is an important issue in drug manufacturing, because it can put both patients and workers at risk of adverse health effects. As the global therapeutics markets grow and drugs become increasingly more potent, authorities in the U.S., Europe and elsewhere are tightening regulations to increase safety and control exposure. Download this eBook to learn more.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!